12 jul: Aktier/åbning: Hele C20 i rødt
12 jul: G4S lover stor indsats for at sikre OL-vagter
12-07-2012 09:37:00

Actelion Launches First Job Cuts

Relateret indhold

By John Revill

ZURICH--Actelion Ltd. (ATLN.VX) will cut its workforce by up to 5% as part of its new cost-cutting program, as Europe's biggest biotechnology company by sales wrestles with the strong Swiss franc and the tough European market.

The cuts will be the first at Actelion since it was founded in 1997.

The company, based in Allschwil, Switzerland, Thursday said it could reduce up to 135 positions from its 2,500-strong workforce by the end of 2012, but didn't say how much it hopes to save from the cuts.

"In order to take full advantage of the growth opportunities ahead of us, we must take decisive action now," said Chief Executive Jean-Paul Clozel.

Around 70 jobs, mostly in R&D and general administration, are likely go at the Allschwil site in Switzerland, where 1,100 employees are currently based. Another 45 currently vacant positions won't be filled, Actelion said.

Pharmaceutical companies have recently been forced to act on steep drug price cuts in Europe and the U.S. and declining revenues as patents on key drugs expire.

Last month, Swiss pharmaceutical company Roche Holding AG (ROG.VX) said it would close a research-and-development site in Nutley, N.J., while Novartis AG (NVS) said in January it needs to save between $1.5 billion and $2.5 billion this year to stay on track.

Actelion, founded by two former Roche scientists, has been dealt a string of product setbacks, and is now banking on a new lung and heart drug called macitentan to become its new blockbuster product.

The company announced that it would be embarking on a cost-saving program in May. At the time, it said earnings wouldn't grow again until 2014 as new medicines and cost cuts would take time to offset falling sales of key pulmonary hypertension drug Tracleer.

Actelion has previously forecast flat core earnings for 2012 as it prepares for declines in sales of Tracleer, which accounts for around 90% of company sales but goes off patent in 2015.

In the first three months of 2012, the company reported a 16% decline in core earnings in Swiss francs--almost double the 9% fall in local currencies--as the currency traded at high levels against the dollar and the euro.

Actelion also Thursday said it is refocusing its R&D efforts toward rare diseases and specialty indications to generate more specialty franchises.

At 0704 GMT, Actelion shares were down CHF0.31, or 0.8%, at CHF40.56.

Write to John Revill at john.revill@dowjones.com

(END) Dow Jones Newswires

July 12, 2012 03:37 ET (07:37 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

DSV/Nykredit: Kursmål bliver hævet med 8 pct. før regnskab

28-04-2017 14:21:41
Nykredit hæver kursmålet for DSV-aktien til 400 kr. fra 370 kr. forud for transportkoncernens regnskab i næste uge.Banken vurderer, at DSV står stærkt på markedet og kan begynde at fokusere på organisk vækst, efter at det seneste år primært er gået med at integrere amerikanske UTI Worldwide, der blev købt sidste år for 9,5 mia. kr.- Vi har hævet vores estimater for de kommende år. Derudover har vi..

Novo/Nordea: Sanofi-regnskab indikerer lyspunkt på vækstmarkeder

28-04-2017 11:31:07
Kvartalsregnskabet fra Novo Nordisks store franske rival, Sanofi, vidner om, at diabetesforretningen har haft en en stærk udvikling på vækstmarkederne, mens salget er under pres i USA.Og det er en tendens, som Nordea regner med også kan slå igennem i Novos regnskabstal på onsdag. Det fremgår af et notat.Nordea understreger dog, at det langt fra er ligetil at drage paralleller fra Sanofis regnskab...

Novo-rival slår overskuds- og salgsforventninger i første kvartal - NY

28-04-2017 08:06:11
Den franske medicinalvirksomhed Sanofi, der er blandt Novo Nordisks største konkurrenter, er kommet ud af årets første tre måneder med en bedre indtjening end ventet.I første kvartal endte det justerede overskud per aktie (Business EPS, red.) på 1,42 euro, hvilket var højere end de 1,26 euro, som analytikerne ifølge Bloomberg News havde sat næsen op efter.Den samlede omsætning steg til 8,65 mia. e..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Fredagens aktier: Danske Bank sikrede fem på stribe for C20 Cap
2
DSV/Nykredit: Kursmål bliver hævet med 8 pct. før regnskab
3
Aktier/Nordea: Europa vil slå stærke regnskaber fra USA
4
NKT gennemfører salg af bilkabelforretning
5
A&O: Direktør øger antallet af aktier

Relaterede aktiekurser

Novartis N 76,55 -0,5% Fald i aktiekurs
Novartis AG 77,03 0,0% Fald i aktiekurs
Roche GS 260,30 0,0% Aktiekurs uændret
Actelion N 265,60 -3,0% Fald i aktiekurs
Roche I 260,50 -0,4% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
29. april 2017 13:25:04
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: ReleaseCandidateBuild_20170427.1 - EUROWEB2 - 2017-04-29 13:25:04 - 2017-04-29 13:25:04 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x